Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Gainers
Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday’s Mid-Day Session
Gainers
MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74.
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday’s Mid-Day Session
Gainers
HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday
Gainers
AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.
Twilio, AMTD Digital And Other Big Gainers From Wednesday
U.S. stocks closed mostly higher with the Nasdaq 100 gaining around 100 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
Why Hill International Is Trading Higher By 15%; Here Are 30 Stocks Moving Premarket
Gainers
NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on late filing of its form 10-Q.
Recap Of Thursday’s Biotech Catalysts – End of The Day Summary
Cyclerion Therapeutics (NASDAQ:CYCN) announced positive topline data from its clinical study of CY6463 for the treatment of Cognitive…
ImmunityBio Announces FDA Acceptance Of Biologics License Application For N-803 In BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. ((IBRX), for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder